VU0661013 is primarily utilized in neuroscience research due to its role as a selective negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). This compound is particularly valuable in studying the mechanisms underlying neurological and psychiatric disorders, such as anxiety, depression, and Fragile X syndrome. By modulating mGluR5 activity, VU0661013 helps researchers understand the receptor's influence on synaptic plasticity and neuronal communication. Its application extends to preclinical studies, where it aids in evaluating potential therapeutic strategies for conditions linked to glutamate dysregulation. Additionally, VU0661013 serves as a tool for exploring the broader implications of mGluR5 in cognitive functions and behavior, contributing to the development of targeted pharmacological interventions.